- Page 1 and 2: GASTROINTESTINAL STROMAL TUMORS * m
- Page 3 and 4: ORIGIN OF GASTROINTESTINAL STROMAL
- Page 5: * KIT kinase intracellular domain a
- Page 9 and 10: PATHOLOGY
- Page 11 and 12: PATHOLOGY. II. spindle cell epithel
- Page 13 and 14: PATHOLOGY. IV. Historical classific
- Page 15 and 16: Courtesy of Dr C Corless PATHOLOGY.
- Page 17 and 18: PATHOLOGY. VIII. Assessing malignan
- Page 19 and 20: Estimated proportion surviving 1.0
- Page 21 and 22: DIAGNOSIS
- Page 23 and 24: Initial workup for suspected or est
- Page 25 and 26: ENDOSCOPY. II. Courtesy of Dr R De
- Page 27 and 28: irregular submucosal mass in fundus
- Page 29 and 30: COMPUTED TOMOGRAPHY. I. * diagnosis
- Page 31 and 32: hepatic metastasis (hyperdense enha
- Page 33 and 34: 18 FDG - PET IMAGING. II. large hep
- Page 35 and 36: GIST: CT and 18 FDG - PET compariso
- Page 37 and 38: TRADITIONAL TREATMENT OPTIONS
- Page 39 and 40: TRADITIONAL TREATMENT. II SURGERY F
- Page 41 and 42: TREATMENT. III. SURGERY OF PRIMARY
- Page 43 and 44: TREATMENT. V. HEPATIC ARTERY EMBOLI
- Page 45 and 46: SURGERY. VII. SURVIVAL FOLLOWING TR
- Page 47 and 48: SURGERY. IX. TUMOR RESECTION AS A P
- Page 49 and 50: RECEPTOR TYROSINE KINASE MUTATIONS
- Page 51 and 52: TYROSINE KINASES IN CANCER. II. * 2
- Page 53 and 54: NORMAL KIT RECEPTOR (STEM CELL FACT
- Page 55 and 56: Signalling mechanisms controlling p
- Page 57 and 58:
NORMAL BIOLOGIC FUNCTION OF KIT REC
- Page 59 and 60:
IMATINIB MESYLATE: BACKGROUND * sel
- Page 61 and 62:
IMATINIB MESYLATE MECHANISM OF ACTI
- Page 63 and 64:
IMATINIB MESYLATE SPECTRUM OF ACTIV
- Page 65 and 66:
IMATINIB AND BCR - ABL TK IN CHRONI
- Page 67 and 68:
TRANSLOCATION LEADING TO PHILADELPH
- Page 69 and 70:
IMATINIB TARGETS IN SOLID TUMORS. I
- Page 71 and 72:
IMATINIB TARGETS IN SOLID TUMORS. I
- Page 73 and 74:
IMATINIB TARGETS IN SOLID TUMORS. V
- Page 75 and 76:
IMATINIB TARGETS IN SOLID TUMORS. V
- Page 77 and 78:
IMATINIB TARGETS IN SOLID TUMORS. X
- Page 79 and 80:
IMATINIB TARGETS IN SOLID TUMORS. X
- Page 81 and 82:
IMATINIB TARGETS IN SOLID TUMORS. X
- Page 83 and 84:
% of total IMATINIB TARGETS IN SOLI
- Page 85 and 86:
IMATINIB TARGETS IN SOLID TUMORS. X
- Page 87 and 88:
IMATINIB TARGETS IN SOLID TUMORS. X
- Page 89 and 90:
SECONDARY CYTOGENETIC CHANGES * con
- Page 91 and 92:
IMATINIB TARGETS IN SOLID TUMORS GI
- Page 93 and 94:
IMATINIB TARGETS IN SOLID TUMORS: G
- Page 95 and 96:
IMATINIB TARGETS IN SOLID TUMORS GI
- Page 97 and 98:
Structures of some representative s
- Page 99 and 100:
Imatinib blocks KIT cancer cell KIT
- Page 101 and 102:
SUNITINIB (SUTENT@ ): ORAL MULTI -
- Page 103 and 104:
EFFICACY AND SAFETY OF SUNITINIB IN
- Page 105 and 106:
Kaplan - Meier estimates of time to